



## MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY DRUG LIST

Effective January 1, 2023

As of April 1, 2015, providers must use the web-based ExpressPAth platform to obtain prior authorization of drug treatments.

Register at <https://www.express-path.com>. If you have questions, please call (877) 273-2122.



This drug list is also available online by going to the following site: <https://accredo.com/prescribers/1199>

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program. The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program. Please call 646-473-7160 to initiate the prior authorization process.

The symbol ♦ next to a drug name indicates that this medication is subject to the eviCore Comprehensive Oncology Management Program for drugs prescribed in the treatment of cancer. Please contact (888) 910-1199 for additional assistance.

The symbol [ST] next to a drug name indicates that this medication is non-preferred. Step therapy is designed to provide safe, effective treatment while controlling prescription costs. With step therapy, you are required to try established, lower-cost, clinically appropriate alternatives before progressing to other, more costly medications, such as Preferred Brand-name Drugs.

| 1199 Brand Name  | Generic Description                            | Disease State           | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|------------------|--|-------------------------|------------------|--|--------------|------------|--------------------|
| ABILIFY MAINTENA | ARIPIRAZOLE                                    | MENTAL CONDITIONS       |                  |  |              | YES        | J0401              |
| ACETADOTE        | ACETYLCYSTEINE                                 | ANTIDOTES               |                  |  |              | YES        | J0132              |
| ACTEMRA♦         | TOCILIZUMAB                                    | INFLAMMATORY CONDITIONS | PA               |  |              | YES        | J3262              |
| ADAKVEO          | CRIZANLIZUMAB-TMCA                             | SICKLE CELL DISEASE     | PA               |  |              | YES        | J0791              |
| ADBRY            | TRALOKINUMAB-LDRM                              | ASTHMA & ALLERGY        | PA               |  |              | YES        | C9399, J3590       |
| ADCIRCA          | TADALAFIL                                      | PULMONARY HYPERTENSION  | PA               |  |              | YES        | J8499              |
| ADEMPAS          | RIOCIGUAT                                      | CIRCULATION DISORDERS   | PA               |  |              | YES        | J8499              |
| ADIPEX-P         | PHENTERMINE                                    | WEIGHT LOSS             | PA               |  |              | YES        | J8499              |
| ADVATE           | FACTOR VIII (ANTHEMOPHL FCTR)                  | HEMOPHILIA              |                  |  |              | YES        | J7192              |
| ADYNOVATE        | FACTOR VIII (ANTHEMOPHL FCTR) RECOMB PEGYLATED | HEMOPHILIA              |                  |  |              | YES        | J7207              |
| AFSTYLA          | ANTHEMOPHL FCTR (RECOMB) SINGLE CHAIN          | HEMOPHILIA              |                  |  |              | YES        | J7210              |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description                | Disease State                           | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code               |
|-----------------|------------------------------------|---|------------------|--|--------------|------------|----------------------------------|
| AIMOVIG         | ERENUMAB                           | MIGRAINE                                | PA               |  |              | YES        | C9399, J3590                     |
| AJOVY           | FREMANEZUMAB                       | MIGRAINE                                | PA               |  |              | YES        | J3031                            |
| ALDURAZYME      | LARONIDASE                         | ENZYME DEFICIENCIES                     |                  | CPA                                      |              | YES        | J1931                            |
| ALPHANATE       | FACTOR VIII (ANTIHEMOPHL FCTR)     | HEMOPHILIA                              |                  |  |              | YES        | J7186                            |
| ALPHANINE SD    | FACTOR IX COMPLEX (HUMAN)          | HEMOPHILIA                              |                  |  |              | YES        | J7193                            |
| ALPROLIX        | FACTOR IX Fc FUSION PROTEIN RECOMB | HEMOPHILIA                              |                  |  |              | YES        | J7201                            |
| ALYMSYS◆✦       | BEVACIZUMAB-MALY                   | OPHTHALMIC CONDITIONS/CANCER            | PA               |  |              | YES        | C9142 (Q5126 EFF: 1/1/23)        |
| AMPYRA          | DALFAMPRIDINE                      | MULTIPLE SCLEROSIS                      | PA               |  |              | YES        | J8499                            |
| AMVUTTRA        | VUTRISIRAN SODIUM                  | AMYLOIDOSIS                             | PA               |  |              | YES        | C9399, J3490                     |
| ANDEXXA         | COAGULATION FACTOR XA              | HEMATOLOGY                              |                  |  |              | YES        | J7169                            |
| APOKYN          | APOMORPHINE HCL                    | MISCELLANEOUS CNS DISORDERS             |                  |  |              | YES        | J0364                            |
| APRETUDE        | CABOTEGRAVIR                       | HIV                                     | PA               |  |              | YES        | C9399, J3490 (J0739 EFF: 7/1/22) |
| ARALAST NP      | ALPHA-1-PROTEINASE INHIBITOR       | RESPIRATORY CONDITIONS                  | PA               |  |              | YES        | J0256                            |
| ARANESP◆        | DARBEPOETIN ALFA                   | BLOOD CELL DEFICIENCY                   | PA               |  |              | YES        | J0881                            |
| ARCALYST        | RILONACEPT                         | CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES | PA               |  |              | YES        | J2793                            |
| ARISTADA        | ARIPIRAZOLE LAUROXIL INJ           | MENTAL CONDITIONS                       |                  |  |              | YES        | J1944                            |
| ARISTADA INITIO | ARIPIRAZOLE LAUROXIL INJ           | MENTAL CONDITIONS                       |                  |  |              | YES        | J1943                            |
| ASCENIV         | IMMUNE GLOBULIN – IV               | IMMUNE DEFICIENCY                       | PA               |  |              | YES        | J1554                            |
| ATGAM           | LYMPHOCYTE IMMUNE GLOBULIN         | TRANSPLANT                              | PA               |  |              | YES        | J7504                            |
| AUBAGIO         | TERIFLUNOMIDE                      | MULTIPLE SCLEROSIS                      | PA               |  |              | YES        | J8499                            |
| AUSTEDO         | DEUTETRABENAZINE                   | MISCELLANEOUS SPECIALTY CONDITIONS      | PA               |  |              | YES        | J8499                            |
| AVASTIN ◆       | BEVACIZUMAB                        | OPHTHALMIC CONDITIONS                   | PA               |  |              | YES        | C9257                            |
| AVEED           | TESTOSTERONE UNDECANOATE           | ENDOCRINE DISORDERS                     | PA               |  |              | YES        | J3145                            |
| AVONEX          | INTERFERON BETA-1A                 | MULTIPLE SCLEROSIS                      | PA               |  |              | YES        | J1826, Q3027                     |
| AVSOLA          | INFLIXIMAB-AXXQ                    | INFLAMMATORY CONDITIONS                 | PA               |  |              | YES        | Q5121                            |
| BELVIQ XR       | LORCASERIN                         | WEIGHT LOSS                             | PA               |  |              | YES        | J8499                            |
| BENEFIX         | FACTOR VIII (ANTIHEMOPHL FCTR)     | HEMOPHILIA                              |                  |  |              | YES        | J7195                            |
| BENLYSTA IV     | BELIMUMAB                          | INFLAMMATORY CONDITIONS                 | PA               |  |              | YES        | J0490                            |
| BENLYSTA SC     | BELIMUMAB                          | INFLAMMATORY CONDITIONS                 | PA               |  |              | YES        | C9399, J3590                     |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name            | Generic Description          | Disease State                      | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|----------------------------|------------------------------|------------------------------------|------------------|--|--------------|------------|--------------------|
| BENZPHETAMINE              | BENZPHETAMINE                | WEIGHT LOSS                        | PA               |  |              | YES        | J3490              |
| BEOVU                      | BROLUCIZUMAB-DBLL            | OPHTHALMIC CONDITIONS              | PA               |  |              | YES        | J0179              |
| BERINERT                   | C1 ESTERASE INHIBITOR        | HEREDITARY ANGIOEDEMA              | PA               |  |              | YES        | J0597              |
| BETASERON                  | INTERFERON BETA-1B           | MULTIPLE SCLEROSIS                 | PA               |  |              | YES        | J1830              |
| BEVACIZUMAB                | BEVACIZUMAB                  | OPHTHALMIC CONDITIONS              | PA               |  |              | YES        | C9257, J7999       |
| BIVIGAM                    | IMMUNE GLOBULIN - IV         | IMMUNE DEFICIENCY                  | PA               |  |              | YES        | 90283, J1556       |
| BONIVA (IV)                | IBANDRONATE                  | OSTEOPOROSIS                       | PA               |  |              | YES        | J1740              |
| BOTOX                      | BOTULINUM TOXIN A            | NEUROMUSCULAR CONDITIONS           | PA               |  |              | YES        | J0585              |
| BRINEURA                   | CERLIPONASE ALFA             | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              | YES        | J0567              |
| CABENUVA                   | CABOTEGRAVIR                 | HIV                                | PA               |  |              | YES        | J0741              |
| CABLIVI                    | CAPLACIZUMAB-YHDP            | BLOOD CELL DEFICIENCY              | PA               |  |              | YES        | C9047              |
| CALCIUM DISODIUM VERSENATE | EDETATE CALCIUM DISODIUM     | ANTIDOTES                          |                  |  |              | YES        | J0600              |
| CARIMUNE NF                | IMMUNE GLOBULIN - IV         | IMMUNE DEFICIENCY                  | PA               |  |              | YES        | 90283, J1566       |
| CELLCEPT                   | MYCOPHENOLATE MOFETIL        | TRANSPLANT                         |                  |  |              | YES        | J7517, J7599       |
| CEPROTIN                   | PROTEIN C CONCENTRATE, HUMAN | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              | YES        | J2724              |
| CERDELGA                   | ELIGLUSTAT                   | ENZYME DEFICIENCIES                |                  | CPA                                      |              | YES        | J8499              |
| CEREZYME                   | IMIGLUCERASE                 | ENZYME DEFICIENCIES                |                  | CPA                                      |              | YES        | J1786              |
| CHEMET                     | SUCCIMER                     | IRON TOXICITY                      | PA               |  |              | YES        | J8499              |
| CHENODAL                   | CHENODIOL                    | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              | YES        | NO HCPC            |
| CHORIONIC GONADOTROPIN     | GONADOTROPIN, CHORIONIC      | ENDOCRINE DISORDERS                |                  |  |              | YES        | J0725              |
| CIDOFOVIR                  | CIDOFOVIR                    | VIRAL INFECTIONS                   |                  |  |              | YES        | J0740              |
| CIMERLI                    | RANIBIZUMAB-EQRN             | OPHTHALMIC CONDITIONS              | PA               |  |              | YES        | C9399, J3590       |
| CIMZIA                     | CERTOLIZUMAB PEGOL           | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | J0717              |
| CINQAIR                    | RESLIZUMAB                   | RESPIRATORY CONDITIONS             | PA               |  |              | YES        | C9481, J2786       |
| CINRYZE                    | C1 ESTERASE INHIBITOR        | HEREDITARY ANGIOEDEMA              | PA               |  |              | YES        | J0598              |
| CLEVIPREX                  | CLEVIDIPINE                  | CAARDIOVASCULAR DISEASE            |                  |  |              | YES        | C9248              |
| COAGADEX                   | FACTOR X HUMAN               | HEMOPHILIA                         |                  | CPA                                      |              | YES        | J7175              |
| CONTRAVE                   | NALTREXONE/BUPROPRION        | WEIGHT LOSS                        | PA               |  |              | YES        | J3490              |
| COPAXONE                   | GLATIRAMER ACETATE           | MULTIPLE SCLEROSIS                 | PA               |  |              | YES        | J1595              |
| CORIFACT                   | FACTOR XIII                  | HEMOPHILIA                         |                  |  |              | YES        | J7180              |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name      | Generic Description                 | Disease State            | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code               |
|----------------------|-------------------------------------|--------------------------|------------------|--|--------------|------------|----------------------------------|
| CORTROPHIN GEL       | REPOSITORY CORTICOTROPIN            | MISCELLANEOUS CONDITIONS | PA               |  |              | YES        | J3490                            |
| COSENTYX             | SECUKINUMAB                         | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | C9399, J3590                     |
| CRESEMBA             | ISAVUCONAZONIUM SULFATE             | ANTIFUNGAL AGENTS        |                  |  |              | YES        | J1833                            |
| CROFAB               | CROTALIDAE POLYVALENT IMMUNE FAB    | ANTIDOTES                |                  |  |              | YES        | J0840                            |
| CRYSVITA◆            | BUROSUMAB-TWZA                      | METABOLIC DISORDER       | PA               |  |              | YES        | J0584                            |
| CUTAQUIG             | IMMUNE GLOBULIN [HUMAN]-HIPP        | IMMUNE DEFICIENCY        | PA               |  |              | YES        | 90284, J3590 (J1551 EFF: 7/1/22) |
| CUVITRU              | IMMUNE GLOBULIN - SQ                | IMMUNE DEFICIENCY        | PA               |  |              | YES        | J1555                            |
| CYTOGAM              | CYTOMEGALOVIRUS IMMUNE GLOB         | IMMUNE DEFICIENCY        |                  | CPA                                      |              | YES        | 90291, J0850                     |
| CYTOVENE             | GANCICLOVIR                         | VIRAL INFECTIONS         |                  |  |              | YES        | J1570                            |
| DALFAMPRIDINE        | DALFAMPRIDINE                       | MULTIPLE SCLEROSIS       | PA               |  |              | YES        | J8499                            |
| DDAVP                | DESMOPRESSIN ACETATE                | ENDOCRINE DISORDERS      |                  |  |              | YES        | J2597                            |
| DEPO-TESTOSTERONE    | TESTOSTERONE CYPIONATE              | ENDOCRINE DISORDERS      | PA               |  |              | YES        | J1071                            |
| DESFERAL             | DEFEROXAMINE MESYLATE               | IRON TOXICITY            |                  |  |              | YES        | J0895                            |
| DESMOPRESSIN ACETATE | DESMOPRESSIN ACETATE                | ENDOCRINE DISORDERS      |                  |  |              | YES        | J2597                            |
| DEXTENZA             | DEXAMETHASONE                       | OPHTHALMIC CONDITIONS    |                  |  |              | YES        | J1096                            |
| DEXYCU               | DEXAMETHASONE                       | OPHTHALMIC CONDITIONS    |                  |  |              | YES        | J1095                            |
| DIETHYLPROPION       | DIETHYLPROPION                      | WEIGHT LOSS              | PA               |  |              | YES        | J3490                            |
| DIGIFAB              | DIGOXIN IMMUNE FAB                  | ANTIDOTES                |                  |  |              | YES        | J1162                            |
| DOPTELET             | AVATROMBOPAG                        | THROMBOCYTOPENIA         | PA               |  |              | YES        | C9399, J8499                     |
| DUOPA                | CARBIDOPA/LEVADOPA                  | NEUROLOGICAL DISORDERS   |                  |  |              | YES        | J7340                            |
| DUPIXENT             | DUPILUMAB                           | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | C9399, J3590                     |
| DUROLANE             | SODIUM HYALURONATE, HYALURONIC ACID | OSTEOARTHRITIS           | PA               |  | ST           | YES        | J7318                            |
| DURYSTA              | BIMATOPROSTIL                       | OPHTHALMIC CONDITIONS    | PA               |  |              | YES        | J7351                            |
| DYLOJECT             | DICLOFENAC SODIUM INJ               | PAIN MANAGEMENT          |                  |  |              | YES        | J1130                            |
| DYSPORT              | ABOBOTULINUMTOXINA                  | NEUROMUSCULAR CONDITIONS | PA               |  |              | YES        | J0586                            |
| EGRIFTA              | TESAMORELIN ACETATE                 | ENDOCRINE DISORDERS      | PA               |  |              | YES        | C9399, J3490                     |
| ELAPRASE             | IDURSULFASE                         | ENZYME DEFICIENCIES      |                  | CPA                                      |              | YES        | J1743                            |
| ELELYSO              | TALIGLUCERASE ALFA                  | ENZYME DEFICIENCIES      |                  | CPA                                      |              | YES        | J3060                            |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name     | Generic Description                | Disease State                      | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code                        |
|---------------------|------------------------------------|------------------------------------|------------------|--|--------------|------------|---|
| ELOCTATE            | FACTOR IX Fc FUSION PROTEIN RECOMB | HEMOPHILIA                         |                  | CPA                                      |              | YES        | J7205                                     |
| EMFLAZA             | FACTOR IX Fc FUSION PROTEIN RECOMB | MUSCULAR DYSTROPHY                 | PA               |  |              | YES        | J8499                                     |
| EMGALITY            | GALCANEZUMAB                       | MIGRAINE                           | PA               |  |              | YES        | C9399, J3590                              |
| EMPAVELI            | PEGCETACOPLAN                      | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              |            | C9399, J3490                              |
| ENBREL              | ETANERCEPT                         | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | J1438                                     |
| ENDARI              | L-GLUTAMINE                        | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              | YES        | J8499                                     |
| ENJAYMO             | SUTINLIMAB-JOME                    | MISCELLANEOUS CONDITIONS           | PA               |  |              | YES        | (C9094 EFF: 7/1/22); (J1302 EFF: 10/1/22) |
| ENSPRYNG            | SATRALIZUMAB-MWGE                  | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              | YES        | C9399, J3590                              |
| ENTYVIO             | VEDOLIZUMAB                        | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | J3380                                     |
| EPCLUSA             | SOFOSBUVIR/VELPATASVIR             | HEPATITIS C                        | PA               |  |              | YES        | J8499                                     |
| EPIDIOLEX           | CANNABIDIOL                        | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              | YES        | J8499                                     |
| EPOGEN◆             | EPOETIN ALFA                       | BLOOD CELL DEFICIENCY              | PA               |  |              | YES        | J0885, Q4081                              |
| EPOPROSTENOL SODIUM | EPOPROSTENOL NA                    | PULMONARY HYPERTENSION             | PA               |  |              | YES        | J1325                                     |
| ESBRIET             | PIRFENIDONE                        | IDIOPATHIC PULMONARY FIBROSIS      | PA               |  |              | YES        | J8499                                     |
| ESPEROCT            | ANTIHEMOPHILIC FACTOR VIII         | HEMOPHILIA                         |                  |  |              | YES        | J7199                                     |
| EUFLEXXA            | SODIUM HYALURONATE                 | OSTEOARTHRITIS                     | PA               |  |              | YES        | J7323                                     |
| EVENITY             | ROMOSOZUMAB-AQQG                   | OSTEOPOROSIS                       | PA               |  |              | YES        | J3111                                     |
| EVKEEZA             | EVINACUMAB-DGNB                    | HIGH BLOOD CHOLESTEROL             | PA               |  |              | YES        | J1305                                     |
| EVRYSDI             | RISDIPLAM                          | SPINAL MUSCULAR ATROPHY            |                  | CPA                                      |              | NO         | J8499                                     |
| EXJADE              | DEFERASIROX                        | IRON TOXICITY                      | PA               |  |              | YES        | J8499                                     |
| EXTAVIA             | INTERFERON BETA-1B                 | MULTIPLE SCLEROSIS                 | PA               |  |              | YES        | J1830                                     |
| EYLEA               | AFLIBERCEPT                        | OPHTHALMIC CONDITIONS              | PA               |  |              | YES        | J0178                                     |
| FABRAZYME           | AGALSIDASE                         | ENZYME DEFICIENCIES                |                  | CPA                                      |              | YES        | J0180                                     |
| FASENRA             | BENRALIZUMAB                       | RESPIRATORY CONDITIONS             | PA               |  |              | YES        | J0517                                     |
| FEIBA NF            | ANTI-INHIBITOR COAGULANT COMP.     | HEMOPHILIA                         |                  |  |              | YES        | J7198                                     |
| FENSOLVI            | LEUPROLIDE ACETATE DEPOT           | ENDOCRINE DISORDERS                | PA               |  |              | YES        | J1951                                     |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name  | Generic Description                   | Disease State               | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code  |
|------------------|---------------------------------------|-----------------------------|------------------|--|--------------|------------|---------------------|
| FERRIPROX        | DEFERIPRONE                           | IRON TOXICITY               | PA               |  |              | YES        | J8499               |
| FIBRYGA          | FIBRINOGEN                            | HEMATOLOGY                  |                  |  |              | YES        | J7177               |
| FIRAZYR          | ICATIBANT ACETATE                     | HEREDITARY ANGIOEDEMA       | PA               |  |              | YES        | J1744               |
| FIRDAPSE         | AMIFAMPRIDINE                         | MUSCULAR DYSTROPHY          |                  | CPA                                      |              | YES        | J8499               |
| FLEBOGAMMA DIF   | IMMUNE GLOBULIN - IV                  | IMMUNE DEFICIENCY           | PA               |  |              | YES        | 90283, J1572        |
| FLOLAN           | EPOPROSTENOL NA                       | PULMONARY HYPERTENSION      | PA               |  |              | YES        | J1325               |
| FOLLISTIM AQ     | FOLLITROPIN BETA, RECOMB              | ENDOCRINE DISORDERS         |                  |  |              | YES        | S0128               |
| FORTEO           | TERIPARATIDE                          | OSTEOPOROSIS                | PA               |  |              | YES        | J3110               |
| FOSCAVIR         | FOSCARNET SODIUM                      | VIRAL INFECTIONS            |                  |  |              | YES        | J1455               |
| FUZEON           | ENFUVRTIDE                            | HIV                         |                  |  |              | YES        | J1324               |
| GALAFOLD         | MIGALASTAT                            | ENZYME DEFICIENCIES         | PA               |  |              | YES        | C9399, J8499        |
| GAMASTAN S-D     | IMMUNE GLOBULIN - IM                  | IMMUNE DEFICIENCY           | PA               |  |              | YES        | 90281, J1460, J1560 |
| GAMIFANT         | EMAPALUMAB-LZSG                       | MISCELLANEOUS CONDITIONS    | PA               |  |              | YES        | J9210               |
| GAMMAGARD LIQUID | IMMUNE GLOBULIN - IV                  | IMMUNE DEFICIENCY           | PA               |  |              | YES        | 90283, 90284, J1569 |
| GAMMAGARD S-D    | IMMUNE GLOBULIN - IV                  | IMMUNE DEFICIENCY           | PA               |  |              | YES        | 90283, J1566        |
| GAMMAKED         | IMMUNE GLOBULIN - IV/SQ               | IMMUNE DEFICIENCY           | PA               |  |              | YES        | 90283, 90284, J1561 |
| GAMMAPLEX        | IMMUNE GLOBULIN - IV                  | IMMUNE DEFICIENCY           | PA               |  |              | YES        | 90283, J1557        |
| GAMUNEX-C        | IMMUNE GLOBULIN - IV                  | IMMUNE DEFICIENCY           | PA               |  |              | YES        | 90283, 90284, J1561 |
| GEL-ONE          | HYALURONATE SODIUM                    | OSTEOARTHRITIS              | PA               |  | ST           | YES        | J7326               |
| GELSYN-3         | HYALURONATE SODIUM                    | OSTEOARTHRITIS              | PA               |  | ST           | YES        | J7328               |
| GENOTROPIN       | SOMATROPIN                            | GROWTH DEFICIENCY           | PA               |  |              | YES        | J2941               |
| GENVISC 850      | HYALURONATE SODIUM                    | OSTEOARTHRITIS              | PA               |  | ST           | YES        | J7320, Q9980        |
| GILENYA          | FINGOLIMOD HYDROCHLORIDE              | MULTIPLE SCLEROSIS          | PA               |  |              | YES        | J8499               |
| GIVLAARI         | GIVOSIRAN                             | MISCELLANEOUS CONDITIONS    | PA               |  |              | YES        | J0223               |
| GLASSIA          | ALPHA-1-PROTEINASE INHIBITOR          | RESPIRATORY CONDITIONS      | PA               |  |              | YES        | J0257               |
| GLATOPA          | GLATIRAMER ACETATE                    | MULTIPLE SCLEROSIS          | PA               |  |              | YES        | J1595               |
| GRASTEK          | TIMOTHY GRASS POLLEN ALLERGEN EXTRACT | ASTHMA AND ALLERGY          | PA               |  |              | YES        | J3590, C9399        |
| H.P. ACTHAR GEL  | CORTICOTROPIN                         | MISCELLANEOUS CNS DISORDERS | PA               |  |              | YES        | J0800               |
| HAEGARDA         | C1 ESTERASE INHIBITOR                 | HEREDITARY ANGIOEDEMA       | PA               |  |              | YES        | J0599               |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name                 | Generic Description                            | Disease State                              | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|---------------------------------|--|--|------------------|--|--------------|------------|--------------------|
| HARVONI                         | LEDIPASVIR/SOFOSBUVIR                          | HEPATITIS C                                | PA               |  |              | YES        | J8499              |
| HEMGENIX†                       | ETRANACOGENE<br>DEZAPARVOVEC - DRLB            | HEMOPHILIA                                 |                  | CPA                                      |              | YES        | C9399, J3590       |
| HELIXATE FS                     | FACTOR VIII (ANTIHEMOPHL FCTR)                 | HEMOPHILIA                                 |                  |  |              | YES        | J7192              |
| HEMLIBRA                        | EMICIZUMAB                                     | HEMOPHILIA                                 |                  |  |              | YES        | J7170              |
| HEMOFIL M                       | FACTOR VIII (ANTIHEMOPHL FCTR)                 | HEMOPHILIA                                 |                  |  |              | YES        | J7190              |
| HEPAGAM B                       | HEP.B IMMUNE GLOB/MALTOSE                      | HEPATITIS B                                |                  |  |              | YES        | J1571, J1573       |
| HETLIOZ                         | TASIMELTEON                                    | MISCELLANEOUS<br>SPECIALTY CONDITIONS      | PA               |  |              | YES        | J8499              |
| HIZENTRA                        | IMMUNE GLOBULIN- SQ                            | IMMUNE DEFICIENCY                          | PA               |  |              | YES        | 90284, J1599       |
| HUMATE-P                        | FACTOR VIII (ANTIHEMOPHL FCTR)                 | HEMOPHILIA                                 |                  |  |              | YES        | J7187              |
| HUMATROPE                       | SOMATROPIN                                     | GROWTH DEFICIENCY                          | PA               |  |              | YES        | J2941              |
| HUMIRA                          | ADALIMUMAB                                     | INFLAMMATORY<br>CONDITIONS                 | PA               |  |              | YES        | J0135              |
| HYALGAN                         | SODIUM HYALURONATE                             | OSTEOARTHRITIS                             | PA               |  | ST           | YES        | J7321              |
| HYDROXYPROGESTERONE<br>CAPROATE | HYDROXYPROGESTERONE<br>CAPROATE                | MISCELLANEOUS<br>SPECIALTY CONDITIONS      | PA               |  |              | YES        | J1726              |
| HYMOVIS                         | HYALURONIC ACID                                | OSTEOARTHRITIS                             | PA               |  | ST           | YES        | C9471, J7322       |
| HYPERHEP B S-D                  | HEPATITIS B IMMUNE GLOBULIN                    | HEPATITIS B                                |                  |  |              | YES        | 90371              |
| HYPERRAB S-D                    | RABIES IMMUNE GLOBULIN                         | IMMUNE DEFICIENCY                          |                  |  |              | YES        | 90375              |
| HYQVIA                          | IMMUNE GLOBULIN - SQ                           | IMMUNE DEFICIENCY                          | PA               |  |              | YES        | J1575              |
| ICATIBANT                       | ICATIBANT                                      | HEREDITARY ANGIOEDEMA                      | PA               |  |              | YES        | J1744              |
| IDELVION                        | FACTOR IX ALBUMIN FUSION<br>PROTEIN RECOMB     | HEMOPHILIA                                 |                  |  |              | YES        | J7202              |
| ILARIS                          | CANAKINUMAB                                    | CRYOPYRIN-ASSOCIATED<br>PERIODIC SYNDROMES | PA               |  |              | YES        | J0638              |
| ILUMYA                          | TILDRAKIZUMAB                                  | INFLAMMATORY<br>CONDITIONS                 | PA               |  |              | YES        | J3245              |
| ILUVIEN                         | FLUOCINOLONE ACETONIDE<br>INTRAVITREAL IMPLANT | OPHTHALMIC CONDITIONS                      |                  |  |              | YES        | J7313              |
| IMCIVREE                        | SETMELANOTIDE                                  | ENDOCRINE DISORDERS                        | PA               |  |              | YES        | J3490, J3590       |
| IMOGAM RABIES-HT                | RABIES IMMUNE GLOBULIN                         | IMMUNE DEFICIENCY                          |                  |  |              | YES        | 90376              |
| INCRELEX                        | MECASERMIN                                     | GROWTH DEFICIENCY                          | PA               |  |              | YES        | J2170              |
| INFLECTRA                       | INFLIXIMAB-DYYB                                | INFLAMMATORY<br>CONDITIONS                 | PA               |  |              | YES        | Q5103              |
| INGREZZA                        | VALBENAZINE                                    | MISCELLANEOUS<br>SPECIALTY CONDITIONS      | PA               |  |              | YES        | J8499              |
| IXINITY                         | COAGULATION FACTOR IX<br>RECOMB                | HEMOPHILIA                                 |                  |  |              | YES        | J7195              |

† Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name      | Generic Description                     | Disease State            | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code               |
|----------------------|---|--------------------------|------------------|--|--------------|------------|----------------------------------|
| JADENU               | DEFERASIROX                             | IRON TOXICITY            | PA               |  |              | YES        | J8499                            |
| JETREA               | OCRIPLASMIN                             | OPHTHALMIC CONDITIONS    |                  |  |              | YES        | J7316                            |
| JVI                  | ANTIHEMOPHILIC FACTOR, AHF, FACTOR VIII | HEMOPHILIA               |                  |  |              | YES        | J7208                            |
| JUXTAPID             | LOMITAPIDE                              | HYPERCHOLESTEROLEMIA     | PA               |  |              | YES        | J8499                            |
| JYNARQUE             | TOLVAPTAN                               | MISCELLANEOUS CONDITIONS | PA               |  |              | YES        | J8499                            |
| KALBITOR             | ECALLANTIDE                             | HEREDITARY ANGIOEDEMA    | PA               |  |              | YES        | J1290                            |
| KALYDECO             | IVACAFTOR                               | CYSTIC FIBROSIS          | PA               |  |              | YES        | J8499                            |
| KANUMA               | SEBELIPASE ALFA                         | ENZYME DEFICIENCIES      |                  | CPA                                      |              | YES        | C9478, J2840                     |
| KCENTRA              | PROTHROMBIN COMPLEX HUMAN               | HEMOPHILIA               |                  |  |              | YES        | J7168                            |
| KENALOG              | TRIAMCINOLONE ACETONIDE                 | INFLAMMATORY CONDITIONS  |                  |  |              | YES        | J3301                            |
| KESIMPTA             | OFATUMUMAB                              | MULTIPLE SCLEROSIS       | PA               |  |              | YES        | J3490                            |
| KEVZARA              | SARILUMAB                               | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | C9399, J3590                     |
| KINERET              | ANAKINRA                                | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | J3590                            |
| KOATE-DVI            | FACTOR VIII (ANTIHEMOPHL FCTR)          | HEMOPHILIA               |                  |  |              | YES        | J7190                            |
| KOGENATE FS          | FACTOR VIII (ANTIHEMOPHL FCTR)          | HEMOPHILIA               |                  |  |              | YES        | J7192                            |
| KORLYM               | MIFEPRISTONE                            | ENDOCRINE DISORDERS      | PA               |  |              | YES        | J8499                            |
| KOVALTRY             | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB   | HEMOPHILIA               |                  |  |              | YES        | J7211                            |
| KRYSTEXXA            | PEGLOTICASE                             | GOUT                     | PA               |  |              | YES        | J2507                            |
| KUVAN                | SAPROPTERIN DIHYDROCHLORIDE             | ENDOCRINE DISORDERS      | PA               |  |              | YES        | J8499                            |
| KYLEENA              | LEVONORGESTREL                          | CONTRACEPTIVE            |                  |  |              | YES        | J7296                            |
| LANREDOTIDE (CIPLA)◆ | LANREOTIDE                              | ENDOCRINE DISORDERS      | PA               |  |              | YES        | J1932                            |
| LANREOTIDE           | LANREOTIDE                              | ENDOCRINE DISORDERS      | PA               |  |              | YES        | J1930                            |
| LEMTRADA             | ALEMTUZUMAB                             | MULTIPLE SCLEROSIS       | PA               |  |              | YES        | J0202                            |
| LEQVIO               | INCLISIRAN                              | HIGH BLOOD CHOLESTEROL   | PA               |  |              | YES        | C9399, J3490 (J1306 EFF: 7/1/22) |
| LETAIRIS             | AMBRISENTAN                             | PULMONARY HYPERTENSION   | PA               |  |              | YES        | J8499                            |
| LILETTA              | LEVONORGESTREL                          | CONTRACEPTIVE            |                  |  |              | YES        | J7297                            |
| LOMAIRA              | PHENTERMINE                             | WEIGHT LOSS              | PA               |  |              | YES        | J3490                            |
| LUCENTIS             | RANIBIZUMAB                             | OPHTHALMIC CONDITIONS    | PA               |  |              | YES        | J2778                            |
| LUMIZYME             | ALGLUCOSIDASE ALFA                      | ENZYME DEFICIENCIES      |                  | CPA                                      |              | YES        | J0221                            |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.



| 1199 Brand Name       | Generic Description                      | Disease State                         | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code           |
|-----------------------|--|---------------------------------------|------------------|--|--------------|------------|------------------------------|
| LUPANETA              | LEUPROLIDE DEPOT/<br>NORETHINDRONE       | MISCELLANEOUS<br>CONDITIONS           | PA               |  |              | YES        | C9399, J3490                 |
| LUPRON DEPOT PED◆     | LEUPROLIDE DEPOT                         | MISCELLANEOUS<br>CONDITIONS           | PA               |  |              | YES        | J1950                        |
| LUPRON DEPOT◆         | LEUPROLIDE DEPOT                         | MISCELLANEOUS<br>CONDITIONS           | PA               |  |              | YES        | J1950, J9217                 |
| LUXTURNA              | VORETIGENE NAPARVOVEC                    | OPHTHALMIC CONDITIONS                 | PA               |  |              | YES        | J3398                        |
| MAKENA                | HYDROXYPROGESTERONE<br>CAPROATE          | MISCELLANEOUS<br>SPECIALTY CONDITIONS | PA               |  |              | YES        | J1726                        |
| MAVYRET               | GLECAPREVIR/PIBRENTASVIR                 | HEPATITIS C                           | PA               |  |              | YES        | J8499                        |
| MIACALCIN             | CALCITONIN                               | BONE CONDITIONS                       |                  |  |              | YES        | J0630                        |
| MIRCERA               | EPOETIN BETA                             | BLOOD CELL DEFICIENCY                 | PA               |  |              | YES        | J0887, J0888                 |
| MIRENA                | LEVONORGESTREL                           | CONTRACEPTIVE                         |                  |  |              | YES        | J7298                        |
| MONOCLATE-P           | FACTOR VIII (ANTIHEMOPHL FCTR)           | HEMOPHILIA                            |                  |  |              | YES        | J7190                        |
| MONONINE              | FACTOR IX COMPLEX (HUMAN)                | HEMOPHILIA                            |                  |  |              | YES        | J7193                        |
| MONOVISC              | SODIUM HYALURONATE                       | OSTEOARTHRITIS                        | PA               |  |              | YES        | J7327                        |
| MOUNJARO              | TIRZEPATIDE                              | DIABETES                              | PA               |  |              | YES        | J3490                        |
| MULPLETA              | LUSUTROMBOPAG                            | THROMBOCYTOPENIA                      | PA               |  |              | YES        | C9399, J8499                 |
| MVASI◆                | BEVACIZUMAB-AWWB                         | OPHTHALMIC CONDITIONS                 | PA               |  |              | YES        | Q5107                        |
| MYALEPT               | METRELEPTIN                              | LIPODYSTROPHY                         | PA               |  |              | YES        | J3590, C9399                 |
| MYCOPHENOLATE MOFETIL | MYCOPHENOLATE MOFETIL                    | TRANSPLANT                            |                  |  |              | YES        | J7517                        |
| MYFORTIC              | MYCOPHENOLATE SODIUM                     | TRANSPLANT                            |                  |  |              | YES        | J7518                        |
| MYOBLOC               | BOTULINUM TOXIN TYPE B                   | NEUROMUSCULAR<br>CONDITIONS           | PA               |  |              | YES        | J0587                        |
| NABI-HB               | HEPATITIS B IMMUNE GLOBULIN              | HEPATITIS B                           |                  |  |              | YES        | 90371                        |
| NAGLAZYME             | GALSULFASE                               | ENZYME DEFICIENCIES                   |                  | CPA                                      |              | YES        | J1458                        |
| NATPARA               | PARATHYROID HORMONE                      | ENDOCRINE DISORDERS                   | PA               |  |              | YES        | C9399, J3590                 |
| NEUPOGEN◆             | FILGRASTIM, G-CSF                        | BLOOD CELL DEFICIENCY                 | PA               |  |              | YES        | J1442                        |
| NEXPLANON             | ETONOGESTREL                             | CONTRACEPTIVE                         |                  |  |              | YES        | J7307                        |
| NEXVIAZYME            | AVALGLUCOSIDAE ALFA-NGPT                 | ENZYME DEFICIENCIES                   |                  | CPA                                      |              | YES        | C9085 (J0219<br>EFF: 4/1/22) |
| NIVESTYM◆             | FILGRASTIM-AAFI                          | BLOOD CELL DEFICIENCY                 | PA               |  |              | YES        | Q5110                        |
| NORDITROPIN           | SOMATROPIN                               | GROWTH DEFICIENCY                     | PA               |  |              | YES        | J2941                        |
| NOVAREL               | GONADOTROPIN, CHORIONIC                  | ENDOCRINE DISORDERS                   |                  |  |              | YES        | J0725                        |
| NOVOEIGHT             | FACTOR VIII (ANTIHEMOPHL<br>FCTR) RECOMB | HEMOPHILIA                            |                  |  |              | YES        | J7182                        |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name    | Generic Description                        | Disease State                 | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|--------------------|--|-------------------------------|------------------|--|--------------|------------|--------------------|
| NOVOSEVEN RT       | FACTOR VIIA, RECOMB (BHK CELLS)            | HEMOPHILIA                    |                  |  |              | YES        | J7189              |
| NPLATE             | ROMIPLOSTIM                                | THROMBOCYTOPENIA              | PA               |  |              | YES        | J2796              |
| NUCALA             | MEPOLIZUMAB                                | RESPIRATORY CONDITIONS        | PA               |  |              | YES        | C9473, J2182       |
| NULIBRY            | FOSDENOPTERIN                              | ENZYME DEFICIENCIES           | PA               |  |              | YES        | C9399, J3590       |
| NULOJIX            | BELATACEPT                                 | TRANSPLANT                    | PA               |  |              | YES        | J0485              |
| NUPLAZID           | PIMAVANSERIN                               | MENTAL/NEURO DISORDERS        | PA               |  |              | YES        | J8499              |
| NUTROPIN           | SOMATROPIN                                 | GROWTH DEFICIENCY             | PA               |  |              | YES        | J2941              |
| NUVARING           | ETONOGESTREL/ETHYNYL ESTRADIOL             | CONTRACEPTIVE                 |                  |  |              | YES        | J7295              |
| NUWIQ              | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB      | HEMOPHILIA                    |                  |  |              | YES        | J7209              |
| OBIZUR             | ANTIHEMOPHL FCTR (RECOMB) PORCINE SEQUENCE | HEMOPHILIA                    |                  |  |              | YES        | J7194, J7188       |
| OCREVUS            | OCRELIZUMAB                                | MULTIPLE SCLEROSIS            | PA               |  |              | YES        | J2350              |
| OCTAGAM            | IMMUNE GLOBULIN - IV                       | IMMUNE DEFICIENCY             | PA               |  |              | YES        | 90283, J1568       |
| OCTREOTIDE ACETATE | OCTREOTIDE                                 | ENDOCRINE DISORDERS           |                  |  |              | YES        | J2354              |
| OFEV               | NINTEDANIB                                 | IDIOPATHIC PULMONARY FIBROSIS | PA               |  |              | YES        | J8499              |
| OLUMIANT           | BARICITINIB                                | INFLAMMATORY CONDITIONS       | PA               |  |              | YES        | C9399, J8499       |
| OMNITROPE          | SOMATROPIN                                 | GROWTH DEFICIENCY             | PA               |  |              | YES        | J2941              |
| ONPATTRO           | PATISIRAN                                  | AMYLOIDOSIS                   | PA               |  |              | YES        | J0222              |
| OPSUMIT            | MACITENTAN                                 | PULMONARY HYPERTENSION        | PA               |  |              | YES        | J8499              |
| ORALAIR            | MIXED GRASS POLLENS ALLERGENS EXTRACT      | ASTHMA AND ALLERGY            | PA               |  |              | YES        | C9399, J3590       |
| ORENCIA            | ABATACEPT/MALTOSE                          | INFLAMMATORY CONDITIONS       | PA               |  |              | YES        | J0129              |
| ORENITRAM          | TREPROSTINIL                               | PULMONARY HYPERTENSION        | PA               |  |              | YES        | J8499              |
| ORKAMBI            | LUMACAFTOR/IVACAFTOR                       | CYSTIC FIBROSIS               | PA               |  |              | YES        | J8499              |
| ORTHOVISC          | HYALURONATE SODIUM                         | OSTEOARTHRITIS                | PA               |  |              | YES        | J7324              |
| OTEZLA             | APREMILAST                                 | INFLAMMATORY CONDITIONS       | PA               |  |              | YES        | J8499              |
| OTIPRIO            | CIPROFLOXACIN                              | INFECTIOUS DISEASE            |                  |  |              | YES        | J7342              |
| OXLUMO             | LUMASIRAN                                  | MISCELLANEOUS CONDITIONS      | PA               |  |              | YES        | J0224              |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name          | Generic Description                            | Disease State                      | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|--------------------------|--|------------------------------------|------------------|--|--------------|------------|--------------------|
| OZURDEX                  | DEXAMETHASONE, INTRAVITREAL IMPLANT            | OPHTHALMIC CONDITIONS              |                  |  |              | YES        | J7312              |
| PALYNZIQ                 | PEGVALIASE                                     | METABOLIC DISORDER                 | PA               |  |              | YES        | C9399, J3590       |
| PANZYGA                  | IMMUNE GLOBULIN - IV                           | IMMUNE DEFICIENCY                  | PA               |  |              | YES        | 90283, J1599       |
| PARAGARD                 | INTRAUTERINE COPPER IUD                        | CONTRACEPTIVE                      |                  |  |              | YES        | J7300              |
| PARSABIV                 | ETELCALCETIDE                                  | HORMONAL SUPPLEMENTATION           |                  |  |              | YES        | J0606              |
| PEGASYS ♦                | PEGINTERFERON ALFA-2A                          | HEPATITIS C                        | PA               |  |              | YES        | S0145, J3590       |
| PEGINTRON ♦              | PEGINTERFERON ALFA-2A                          | HEPATITIS C                        | PA               |  |              | YES        | S0148, J3590       |
| PHENDIMETRAZINE          | PHENDIMETRAZINE                                | WEIGHT LOSS                        | PA               |  |              | YES        | J3490              |
| PHOTREXA                 | RIBOFLAVIN 5 PHOSPHATE                         | OPHTHALMIC CONDITIONS              |                  |  |              | YES        | J2787              |
| PLEGRIDY                 | PEGINTERFERON BETA-1A                          | MULTIPLE SCLEROSIS                 | PA               |  |              | YES        | C9399, J3590       |
| PRALUENT                 | ALIROCUMAB                                     | HYPERCHOLESTEROLEMIA               | PA               |  |              | YES        | C9399, J3590       |
| PREGNYL                  | GONADOTROPIN, CHORIONIC                        | ENDOCRINE DISORDERS                |                  |  |              | YES        | J0725              |
| PRIALT                   | ZICONOTIDE ACETATE                             | PAIN MANAGEMENT                    |                  |  |              | YES        | J2278              |
| PRIVIGEN                 | IMMUNE GLOBULIN - IV                           | IMMUNE DEFICIENCY                  | PA               |  |              | YES        | 90283, J1459       |
| PROBUPHINE IMPLANT       | BUPRENORPHINE HCL                              | MISCELLANEOUS SPECIALTY CONDITIONS |                  |  |              | YES        | J0570              |
| PROCRIT ♦                | EPOETIN ALFA                                   | BLOOD CELL DEFICIENCY              | PA               |  |              | YES        | J0885, Q4081       |
| PROFILNINE/PROFILNINE SD | FACTOR IX COMPLEX (HUMAN)                      | HEMOPHILIA                         |                  |  |              | YES        | J7194              |
| PROGESTERONE             | PROGESTERONE                                   | ENDOCRINE DISORDERS                |                  |  |              | YES        | J2675              |
| PROGRAF                  | TACROLIMUS                                     | TRANSPLANT                         |                  |  |              | YES        | J7507, J7525       |
| PROLASTIN-C              | ALPHA-1-PROTEINASE INHIBITOR                   | RESPIRATORY CONDITIONS             | PA               |  |              | YES        | J0256              |
| PROLIA                   | DENOSUMAB                                      | OSTEOPOROSIS                       | PA               |  |              | YES        | J0897              |
| PROMACTA                 | ELTROMBOPAG OLAMINE                            | THROMBOCYTOPENIA                   | PA               |  |              | YES        | J8499              |
| PULMOZYME                | DEOXYRIBONUCLEASE                              | RESPIRATORY CONDITIONS             | PA               |  |              | YES        | J7639              |
| QSYMIA                   | PHENTERMINE; TOPIRAMATE                        | WEIGHT LOSS                        | PA               |  |              | YES        | J8499              |
| RADICAVA                 | EDAVARONE                                      | AMYOTROPHIC LATERAL SCLEROSIS      | PA               |  |              | YES        | J1301              |
| RAPAMUNE                 | SIROLIMUS                                      | TRANSPLANT                         |                  |  |              | YES        | J7520              |
| RAPIVAB                  | PERAMIVIR                                      | ANTIVIRAL AGENTS                   |                  |  |              | YES        | J2547              |
| REBETOL                  | RIBAVIRIN                                      | HEPATITIS C                        | PA               |  |              | YES        | J8499              |
| REBIF                    | INTERFERON BETA-1A/ALBUMIN                     | MULTIPLE SCLEROSIS                 | PA               |  |              | YES        | Q3028              |
| REBINYN                  | FACTOR IX (ANTIHEMOPHILIC FACTOR, RECOMBINANT) | HEMOPHILIA                         |                  |  |              | YES        | J7203              |
| REBLOZYL ♦               | LUSPATERCEPT-AAMT                              | BLOOD MODIFYING                    | PA               |  |              | YES        | J0896              |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name  | Generic Description                             | Disease State            | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code          |
|------------------|---|--------------------------|------------------|--|--------------|------------|-----------------------------|
| RECLAST          | ZOLEDRONIC ACID                                 | OSTEOPOROSIS             | PA               |  |              | YES        | J3489                       |
| RECOMBINATE      | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB           | HEMOPHILIA               |                  |  |              | YES        | J7192                       |
| RELEUKO◆         | FILGRASTIM-AYOW                                 | BLOOD CELL DEFICIENCY    | PA               |  |              | YES        | C9096, (Q5125 EFF: 10/1/22) |
| REMICADE         | INFLIXIMAB                                      | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | J1745                       |
| REMODULIN        | TREPROSTINIL SODIUM                             | PULMONARY HYPERTENSION   | PA               |  |              | YES        | J3285                       |
| RENFLEXIS        | INFLIXIMAB-ABDA                                 | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | Q5104                       |
| REPATHA          | EVOLOCUMAB                                      | HYPERCHOLESTEROLEMIA     | PA               |  |              | YES        | C9399, J3590                |
| RETACRIT◆        | EPOETIN ALFA                                    | BLOOD CELL DEFICIENCY    | PA               |  |              | YES        | Q5105, Q5106                |
| RETAVASE         | PERAMIVIR                                       | VIRAL INFECTIONS         |                  |  |              | YES        | J2993                       |
| REVATIO          | SILDENAFIL CITRATE                              | PULMONARY HYPERTENSION   | PA               |  |              | YES        | J3490, J8499                |
| RIABNI◆          | RITUXIMAB-ARRX                                  | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | Q5123                       |
| RIASTAP          | FIBRINOGEN                                      | HEMATOLOGY               |                  |  |              | YES        | J7178                       |
| RIBAPAK          | RIBAVIRIN                                       | HEPATITIS C              | PA               |  |              | YES        | J8499                       |
| RIBAVIRIN        | RIBAVIRIN                                       | HEPATITIS C              | PA               |  |              | YES        | J8499                       |
| RITUXAN◆✦        | RITUXIMAB                                       | INFLAMMATORY CONDITIONS  | PA               |  | ST           | YES        | J9312                       |
| RIXUBIS          | FACTOR IX, (ANTIHEMOPHILIC FACTOR, RECOMBINANT) | HEMOPHILIA               |                  |  |              | YES        | J7200                       |
| RUCONEST         | C1 ESTERASE INHIBITOR                           | HEREDITARY ANGIOEDEMA    | PA               |  |              | YES        | J0596                       |
| RUXIENCE◆        | RITUXIMAB-PVVR                                  | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | Q5119                       |
| RYPLAZIM         | PLASMINOGEN, HUMAN-TVMH                         | HEMATOLOGY               | PA               |  |              | YES        | C9090 (J2998 EFF: 7/1/22)   |
| SAIZEN           | SOMATROPIN                                      | GROWTH DEFICIENCY        | PA               |  |              | YES        | J2941                       |
| SANDOSTATIN◆     | OCTREOTIDE                                      | ENDOCRINE DISORDERS      |                  |  |              | YES        | J2354                       |
| SANDOSTATIN LAR◆ | OCTREOTIDE                                      | ENDOCRINE DISORDERS      |                  |  |              | YES        | J2353                       |
| SAPHNELO         | ANIFROLUMAB-FNIA                                | LUPUS                    | PA               |  |              | YES        | C9086 (J0491 EFF: 4/1/22)   |
| SAXENDA          | LIRAGLUTIDE                                     | WEIGHT LOSS              | PA               |  |              | YES        | J3490                       |
| SCENESSE         | AFAMELANOTIDE                                   | MISCELLANEOUS CONDITIONS | PA               |  |              | YES        | J7352                       |
| SEROSTIM         | SOMATROPIN                                      | GROWTH DEFICIENCY        | PA               |  |              | YES        | J2941                       |
| SEVENFACT        | FACTOR VIIA RECOMBINANT                         | HEMOPHILIA               |                  |  |              | YES        | J7212                       |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name    | Generic Description         | Disease State                      | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code                         |
|--------------------|-----------------------------|------------------------------------|------------------|--|--------------|------------|--|
| SIGNIFOR LAR       | PASIREOTIDE DIASPARTATE INJ | ENDOCRINE DISORDERS                | PA               |  |              | YES        | C9454, J2502                               |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE          | PULMONARY HYPERTENSION             | PA               |  |              | YES        | J3490, J8499                               |
| SILIQ              | BRODALUMAB                  | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | C9399                                      |
| SIMPONI            | GOLIMUMAB                   | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | C9399, J3590                               |
| SIMPONI ARIA       | GOLIMUMAB                   | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | J1602                                      |
| SIMULECT           | BASILIXIMAB                 | TRANSPLANT                         |                  |  |              | YES        | J0480                                      |
| SINUVA             | MOMETASONE                  | RESPIRATORY CONDITIONS             |                  |  |              | YES        | J7402                                      |
| SKYLA              | LEVONORGESTREL              | CONTRACEPTIVE                      |                  |  |              | YES        | J7301                                      |
| SKYRIZI            | RISANKIZUMAB-RZAA           | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | C9399, J3590                               |
| SKYRIZI IV +       | RISANKIZUMAB-RZAA           | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | C9399, J3590<br>(J2327 EFF: 1/1/23)        |
| SKYSONA            | ELIVALDOGENE AUTOTEMCEL     | NEUROLOGICAL DISORDERS             |                  | CPA                                      |              | YES        | C9399, J3590                               |
| SKYTROFA           | LONAPEGSOMATROPIN-TCGD      | GROWTH DEFICIENCIES                | PA               |  |              | YES        | C9399, J3590                               |
| SODIUM HYALURONATE | SODIUM HYALURONATE          | OSTEOARTHRITIS                     | PA               |  | ST           | YES        | C9399, J3490                               |
| SOLESTA            | DEXTRANOMER/HYALURONATE/SOD | MISCELLANEOUS SPECIALTY CONDITIONS |                  |  |              | YES        | L8605                                      |
| SOLIRIS            | ECULIZUMAB                  | BLOOD MODIFYING                    | PA               |  |              | YES        | J1300                                      |
| SOMATULINE DEPOT ♦ | LANREOTIDE ACETATE          | ENDOCRINE DISORDERS                |                  |  |              | YES        | J1930                                      |
| SOVALDI            | SOFOSBUVIR                  | HEPATITIS C                        | PA               |  |              | YES        | J8499                                      |
| SPEVIGO            | SPELIMAB-SBZO               | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | C9399, J3590                               |
| SPINRAZA           | NUSINERSEN                  | NEUROMUSCULAR CONDITIONS           |                  | CPA                                      |              | YES        | J2326                                      |
| SPRAVATO           | ESKETAMINE                  | MISCELLANEOUS CONDITIONS           | PA               |  |              | YES        | S0013                                      |
| STELARA            | USTEKINUMAB                 | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | J3357                                      |
| STELARA IV         | USTEKINUMAB                 | INFLAMMATORY CONDITIONS            | PA               |  |              | YES        | J3358                                      |
| STRENSIQ           | ASFOTASE ALFA               | ENZYME DEFICIENCIES                | PA               |  |              | YES        | C9399, J3590                               |
| SUPARTZ FX         | HYALURONATE SODIUM          | OSTEOARTHRITIS                     | PA               |  | ST           | YES        | J7321                                      |
| SUSVIMO            | RANIBIZUMAB                 | OPHTHALMIC CONDITIONS              | PA               |  |              | YES        | C9399, J3590, C9093<br>(J2779 EFF: 7/1/22) |
| SYMDEKO            | TEZACAFTOR/IVACAFTOR        | CYSTIC FIBROSIS                    | PA               |  |              | YES        | J8499                                      |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name        | Generic Description                  | Disease State            | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code                  |
|------------------------|--------------------------------------|--------------------------|------------------|--|--------------|------------|-------------------------------------|
| SYNAGIS                | PALIVIZUMAB                          | RSV PREVENTION           | PA               |  |              | YES        | 90378                               |
| SYNERCID               | QUINUPRISTIN/DALFOPRISTIN            | ANTIBIOTICS              |                  |  |              | YES        | J2770                               |
| SYNVISC                | HYALURONATE SODIUM                   | OSTEOARTHRITIS           | PA               |  | ST           | YES        | J7325                               |
| SYNVISC-ONE            | HYALURONATE SODIUM                   | OSTEOARTHRITIS           | PA               |  | ST           | YES        | J7325                               |
| TACROLIMUS             | TACROLIMUS                           | TRANSPLANT               |                  |  |              | YES        | J7507                               |
| TADALAFIL              | TADALAFIL                            | PULMONARY HYPERTENSION   | PA               |  |              | YES        | J8499                               |
| TAKHZYRO               | LANADELUMAB                          | HEREDITARY ANGIOEDEMA    | PA               |  |              | YES        | J0593                               |
| TALTZ                  | IXEKIZUMAB                           | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | C9399                               |
| TAVALISSE              | FOSTAMATINIB                         | THROMBOCYTOPENIA         | PA               |  |              | YES        | J8499                               |
| TECFIDERA              | DIMETHYL FUMARATE                    | MULTIPLE SCLEROSIS       | PA               |  |              | YES        | J8499                               |
| TEFLARO                | CEFTAROLINE                          | INFECTIOUS DISEASE       |                  |  |              | YES        | J0712                               |
| TEGSEDI                | INOTERSEN                            | AMYLOIDOSIS              | PA               |  |              | YES        | C9399, J3490                        |
| TEPEZZA                | TEPROTUMUMAB-TRBW                    | OPHTHALMIC CONDITIONS    | PA               |  |              | YES        | J3241                               |
| TESTOPEL               | TESTOSTERONE PELLETT                 | ENDOCRINE DISORDERS      | PA               |  |              | YES        | J3490, S0189                        |
| TESTOSTERONE ENANTHATE | TESTOSTERONE ENANTHATE               | ENDOCRINE DISORDERS      | PA               |  |              | YES        | J3121                               |
| TEZSPIRE               | TEZEPELUMAB-EKKO                     | ASTHMA & ALLERGY         | PA               |  |              | YES        | C9399, J3590<br>(J2356 EFF: 7/1/22) |
| THYMOGLOBULIN          | LYMPHOCYTE IMMUNE GLOBULIN           | TRANSPLANT               |                  |  |              | YES        | J7511                               |
| TOBI                   | TOBRAMYCIN                           | RESPIRATORY CONDITIONS   |                  |  |              | YES        | J3535, J7682                        |
| TRACLEER               | BOSENTAN                             | PULMONARY HYPERTENSION   | PA               |  |              | YES        | J8499                               |
| TREMFYA                | GUSELKUMAB                           | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | J1628                               |
| TRETEN                 | FACTOR XIII A-SUBUNIT, (RECOMBINANT) | HEMOPHILIA               |                  |  |              | YES        | J7181                               |
| TRILURON               | SODIUM HYALURONATE                   | OSTEOARTHRITIS           | PA               |  | ST           | YES        | J7332                               |
| TRIPTODUR              | TRIPTORELIN                          | MISCELLANEOUS CONDITIONS | PA               |  |              | YES        | J3316                               |
| TRIVISC                | HYALURONATE SODIUM                   | OSTEOARTHRITIS           | PA               |  | ST           | YES        | J7329                               |
| TROGARZO               | IBALIZUMAB                           | HIV                      | PA               |  |              | YES        | J1746                               |
| TRUXIMA◆               | RITUXIMAB - ABBS                     | INFLAMMATORY CONDITIONS  | PA               |  |              | YES        | Q5115                               |
| TYGACIL                | TIGECYCLINE                          | ANTIBIOTICS              |                  |  |              | YES        | J3243                               |
| TYMLOS                 | ABALOPARATIDE                        | OSTEOPOROSIS             | PA               |  |              | YES        | C9399                               |
| TYSABRI                | NATALIZUMAB                          | MULTIPLE SCLEROSIS       | PA               |  |              | YES        | J2323                               |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description                                | Disease State                | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code                          |
|-----------------|--|------------------------------|------------------|--|--------------|------------|---|
| TYVASO          | TREPROSTINIL (TYVASO)                              | PULMONARY HYPERTENSION       | PA               |  |              | YES        | J7686                                       |
| TZIELD✦         | TEPLIZUMAB - MZWW                                  | ENDOCRINE DISORDERS          | PA               |  |              | YES        | C9399, J3590                                |
| ULTOMIRIS       | RAVULIZUMAB-CWVZ                                   | BLOOD MODIFYING              | PA               |  |              | YES        | J1303                                       |
| UPLIZNA         | INEBILIZUMAB-CWVZ                                  | MISCELLANEOUS CONDITIONS     | PA               |  |              | YES        | J1823                                       |
| UPTRAVI         | SELEXIPAG  | PULMONARY HYPERTENSION       | PA               |  |              | YES        | J8499                                       |
| VABYSMO         | FARICIMAB-SVOA                                     | OPHTHALMIC CONDITIONS        | PA               |  |              | YES        | (C9097 EFF:7/1/22);<br>(J2777 EFF: 10/1/22) |
| VAPRISOL        | CONIVAPTAN HYDROCHLORIDE                           | HORMONAL SUPPLEMENTATION     |                  |  |              | YES        | C9488                                       |
| VEGZELMA◆✦      | BEVACIZUMAB-ADCD                                   | OPHTHALMIC CONDITIONS/CANCER | PA               |  |              | YES        | C9399, J3590                                |
| VEKLURY         | REMDESIVIR   | COVID-19                     | PA               |  |              | YES        | J0248                                       |
| VELETRI         | EPOPROSTENOL NA                                    | PULMONARY HYPERTENSION       | PA               |  |              | YES        | J1325                                       |
| VENTAVIS        | ILOPROST   | PULMONARY HYPERTENSION       | PA               |  |              | YES        | Q4074                                       |
| VIEKIRA PAK     | OMBITASVIR, PARITAPREVIR, AND RITONAVIR; DASABUVIR | HEPATITIS C                  | PA               |  |              | YES        | J8499                                       |
| VIMIZIM         | ELOSULFASE ALFA                                    | ENZYME DEFICIENCIES          |                  | CPA                                      |              | YES        | C9022, J1322                                |
| VISCO-3         | HYALURONATE SODIUM                                 | OSTEOARTHRITIS               | PA               |  | ST           | YES        | J7321                                       |
| VISUDYNE        | VERTEPORFIN  | OPHTHALMIC CONDITIONS        |                  |  |              | YES        | J3396                                       |
| VIVITROL        | NALTREXONE MICROSPHERES                            | MISCELLANEOUS CNS DISORDERS  |                  |  |              | YES        | J2315                                       |
| VONVENDI        | VON WILLEBRAND FACTOR (RECOMBINANT)                | HEMOPHILIA                   |                  |  |              | YES        | J7179                                       |
| VOSEVI          | SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR              | HEPATITIS C                  | PA               |  |              | YES        | J8499                                       |
| VOXZOGO         | VOSORITIDE   | ENDOCRINE DISORDERS          | PA               |  |              | YES        | C9399, J3590                                |
| VPRIV           | VELAGLUCERASE ALFA                                 | ENZYME DEFICIENCIES          |                  | CPA                                      |              | YES        | J3385                                       |
| VYEPTI          | EPTINEZUMAB-JJMR                                   | MISCELLANEOUS CONDITIONS     | PA               |  |              | YES        | J3032                                       |
| VYVGART         | EFGARTIGIMOD ALFA-FCAB                             | MISCELLANEOUS CONDITIONS     | PA               |  |              | YES        | C9399, J3590<br>(J9332 EFF: 7/1/22)         |
| WILATE          | VON WILLEBRAND FACTOR COMPLEX (HUMAN)              | HEMOPHILIA                   |                  |  |              | YES        | J7183                                       |
| XELJANZ         | TOFACITINIB  | INFLAMMATORY CONDITIONS      | PA               |  |              | YES        | J8499                                       |
| XEMBIFY         | IMMUNE GLOBULIN - SQ                               | IMMUNE DEFICIENCY            | PA               |  |              | YES        | J1558                                       |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name        | Generic Description              | Disease State                      | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|------------------------|----------------------------------|------------------------------------|------------------|--|--------------|------------|--------------------|
| XENAZINE               | TETRABENAZINE                    | MISCELLANEOUS CNS DISORDERS        | PA               |  |              | YES        | J8499              |
| XENICAL                | ORLISTAT                         | WEIGHT LOSS                        | PA               |  |              | YES        | J3490              |
| XENPOZYME              | OLIPUDASE ALFA-RPCP              | ENZYME DEFICIENCIES                |                  | CPA                                      |              | YES        | C9399, J3590       |
| XEOMIN                 | INCOBOTULINUMTOXINA              | NEUROMUSCULAR CONDITIONS           | PA               |  |              | YES        | J0588              |
| XIAFLEX                | COLLAGENASE CLOSTRIDIUM HIST.    | MISCELLANEOUS SPECIALTY CONDITIONS | PA               |  |              | YES        | J0775              |
| XOLAIR                 | OMALIZUMAB                       | RESPIRATORY CONDITIONS             | PA               |  |              | YES        | J2357              |
| XULANE                 | NORELGESTROMIN/ETHINYL ESTRADIOL | CONTRACEPTIVE                      |                  |  |              | YES        | J7304              |
| XYNTHA/XYNTHA SOLOFUSE | FACTOR VIII (ANTIHEMOPHL FCTR)   | HEMOPHILIA                         |                  |  |              | YES        | J7185              |
| ZARXIO◆                | FILGRASTIM-SNDZ                  | BLOOD CELL DEFICIENCY              | PA               |  |              | YES        | Q5101              |
| ZAVESCA                | MIGLUSTAT                        | ENZYME DEFICIENCIES                |                  | CPA                                      |              | NO         | J8499              |
| ZEMAIRA                | ALPHA-1-PROTEINASE INHIBITOR     | RESPIRATORY CONDITIONS             | PA               |  |              | YES        | J0256              |
| ZEPATIER               | ELBASVIR/GRAZOPRE VIR            | HEPATITIS C                        | PA               |  |              | YES        | J8499              |
| ZILRETTA               | TRIAMCINOLONE MICROSPHERES       | OSTEOARTHRITIS                     |                  |  |              | YES        | J3304              |
| ZINPLAVA               | BEZLOTOXUMAB                     | INFECTIOUS DISEASE                 |                  |  |              | YES        | J0565              |
| ZIRABEV◆               | BEVACIZUMAB                      | OPHTHALMIC CONDITIONS              | PA               |  |              | YES        | Q5118              |
| ZOLADEX◆               | GOSERELIN ACETATE                | ENDOCRINE DISORDERS                | PA               |  |              | YES        | J9202              |
| ZOLEDRONIC ACID◆       | ZOLEDRONIC ACID                  | OSTEOPOROSIS                       | PA               |  |              | YES        | J3489              |
| ZOLGENSMA              | ONASEMNOGENE ABEPARVOVEC-XIOI    | NEUROMUSCULAR CONDITIONS           |                  | CPA                                      |              | YES        | J3399              |
| ZOMACTON               | SOMATROPIN                       | GROWTH DEFICIENCY                  | PA               |  |              | YES        | J2941              |
| ZOMETA 4MG◆            | ZOLEDRONIC ACID                  | CANCER                             | PA               |  |              | YES        | J3489              |
| ZOMETA 5MG             | ZOLEDRONIC ACID                  | OSTEOPOROSIS                       | PA               |  |              | YES        | J3489              |
| ZORBTIVE               | SOMATROPIN                       | GROWTH DEFICIENCY                  | PA               |  |              | YES        | J2941              |
| ZULRESSO               | BREXANOLONE                      | MISCELLANEOUS CONDITIONS           |                  | CPA                                      |              | YES        | J1632              |
| ZYNTEGLO               | BETIBEGLOGENE                    | BLOOD CELL DEFICIENCY              |                  | CPA                                      |              | YES        | C9399, J3590       |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.